Journal of Shanghai Jiao Tong University (Medical Science) >
CTCF regulates lipid metabolism and gene expression in mouse AML12 liver cell line
Received date: 2024-05-03
Accepted date: 2024-05-22
Online published: 2024-09-28
Supported by
National Natural Science Foundation of China(32200432);Natural Science Foundation of Shanghai(23ZR1435700);Innovative Research Team of High-Level Local Universities in Shanghai(SHSMUZLCX20211700);“Two-hundred Talents” Program of Shanghai Jiao Tong University School of Medicine(20171920)
Objective ·To clarify the regulatory role of CCCTC-binding factor (CTCF) in lipid metabolism in liver cells, and explore the mechanisms by which CTCF regulates liver cell gene expression. Methods ·Immortalized AML12 liver cell line was used as a model to investigate the functions of CTCF in liver cells. To stably knock down Ctcf, DNA sequences stably expressing Ctcf shRNA were integrated into AML12 cells through lentivirus. The knockdown efficiency of Ctcf was verified by RT-qPCR and Western blotting. The effects of Ctcf knockdown on cell growth and cell cycle were assessed by performing CCK-8 assay and propidium iodide (PI) staining. Intracellular lipids, labeled with Oil Red O staining, were analyzed and quantified to detect the effect of CTCF on lipid metabolism and lipid droplet accumulation in AML12 cells. Changes in CTCF genome distribution after Ctcf knockdown were analyzed using the Cleavage Under Targets and Tagmentation (CUT&Tag) method. Transcriptome changes in AML12 cells after Ctcf knockdown were quantified by RNA sequencing (RNA-seq). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and gene set enrichment analysis (GSEA) were employed to evaluate the functions of differentially expressed genes. The correlation between gene expression changes and CTCF binding changes was further assessed by performing statistical analyses. Results ·The result of RT-qPCR showed that Ctcf is downregulated 63.4% in mRNA level and 57.7% in protein level (both P<0.05). Assay of the growth curve and cycle phase confirmed that cell proliferation was inhibited in the G1/G0 phase after Ctcf knockdown. After Ctcf knockdown, AML12 cells exhibited spontaneous accumulation of intracellular lipids, indicating dysregulation of lipid metabolism (P<0.05). Genome-wide CTCF binding analysis revealed significant changes, with most differential CTCF peaks showing decreased binding, although a subset of regions exhibited increased CTCF binding. Transcriptome analyses revealed that knocking down Ctcf resulted in significant expression changes in 1 344 genes. These differentially expressed genes were enriched in lipid metabolism pathways. Further analysis showed that genes associated with regions of increased CTCF binding were enriched in pathways related to lipid transport and localization, whereas genes associated with regions of decreased CTCF binding were mainly enriched in processes such as DNA damage repair, apoptosis, and cell cycle regulation. However, the binding changes of CTCF in the genome were not sufficient to lead to the expression changes of their neighboring genes. Conclusion ·CTCF affects the metabolic function of liver cells by regulating the expression of lipid metabolism-related genes. However, the binding changes of CTCF in the genome lack significant correlation with the expression of their neighboring genes, suggesting that CTCF mainly influences liver gene expression through long-distance regulation, possibly by modulating higher-order chromatin structure and enhancer-promoter interactions.
Huaihuang CHEN , Wu ZUO , Qian BIAN . CTCF regulates lipid metabolism and gene expression in mouse AML12 liver cell line[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(9) : 1069 -1082 . DOI: 10.3969/j.issn.1674-8115.2024.09.002
| 1 | ARZATE-MEJíA R G, RECILLAS-TARGA F, CORCES V G. Developing in 3D: the role of CTCF in cell differentiation[J]. Development, 2018, 145(6): dev137729. |
| 2 | KUBO N, ISHII H, XIONG X, et al. Promoter-proximal CTCF binding promotes distal enhancer-dependent gene activation[J]. Nat Struct Mol Biol, 2021, 28(2): 152-161. |
| 3 | LIU Y T, WAN X, LI H, et al. CTCF coordinates cell fate specification via orchestrating regulatory hubs with pioneer transcription factors[J]. Cell Rep, 2023, 42(10): 113259. |
| 4 | BISSERIER M, MATHIYALAGAN P, ZHANG S H, et al. Regulation of the methylation and expression levels of the BMPR2 gene by SIN3a as a novel therapeutic mechanism in pulmonary arterial hypertension[J]. Circulation, 2021, 144(1): 52-73. |
| 5 | NUEBLER J, FUDENBERG G, IMAKAEV M, et al. Chromatin organization by an interplay of loop extrusion and compartmental segregation[J]. Proc Natl Acad Sci U S A, 2018, 115(29): E6697-E6706. |
| 6 | XIANG J F, CORCES V G. Regulation of 3D chromatin organization by CTCF[J]. Curr Opin Genet Dev, 2021, 67: 33-40. |
| 7 | DAVIDSON I F, BARTH R, ZACZEK M, et al. CTCF is a DNA-tension-dependent barrier to cohesin-mediated loop extrusion[J]. Nature, 2023, 616(7958): 822-827. |
| 8 | ROWLEY M J, CORCES V G. Organizational principles of 3D genome architecture[J]. Nat Rev Genet, 2018, 19(12): 789-800. |
| 9 | DEHINGIA B, MILEWSKA M, JANOWSKI M, et al. CTCF shapes chromatin structure and gene expression in health and disease[J]. EMBO Rep, 2022, 23(9): e55146. |
| 10 | HYLE J, ZHANG Y, WRIGHT S, et al. Acute depletion of CTCF directly affects MYC regulation through loss of enhancer-promoter looping[J]. Nucleic Acids Res, 2019, 47(13): 6699-6713. |
| 11 | RAHME G J, JAVED N M, PUORRO K L, et al. Modeling epigenetic lesions that cause gliomas[J]. Cell, 2023, 186(17): 3674-3685.e14. |
| 12 | POULOS R C, THOMS J A I, GUAN Y F, et al. Functional mutations form at CTCF-cohesin binding sites in melanoma due to uneven nucleotide excision repair across the motif[J]. Cell Rep, 2016, 17(11): 2865-2872. |
| 13 | RIBEIRO DE ALMEIDA C, STADHOUDERS R, DE BRUIJN M J, et al. The DNA-binding protein CTCF limits proximal Vκ recombination and restricts κ enhancer interactions to the immunoglobulin κ light chain locus[J]. Immunity, 2011, 35(4): 501-513. |
| 14 | HIRAYAMA T, TARUSAWA E, YOSHIMURA Y, et al. CTCF is required for neural development and stochastic expression of clustered Pcdh genes in neurons[J]. Cell Rep, 2012, 2(2): 345-357. |
| 15 | CHRISTOV M, CLARK A R, CORBIN B, et al. Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities[J]. JCI Insight, 2018, 3(4): e95091. |
| 16 | GOMEZ-VELAZQUEZ M, BADIA-CAREAGA C, LECHUGA-VIECO A V, et al. CTCF counter-regulates cardiomyocyte development and maturation programs in the embryonic heart[J]. PLoS Genet, 2017, 13(8): e1006985. |
| 17 | DUBOIS-CHEVALIER J, OGER F, DEHONDT H, et al. A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation[J]. Nucleic Acids Res, 2014, 42(17): 10943-10959. |
| 18 | WANG R R, QIU X Y, PAN R, et al. Dietary intervention preserves β cell function in mice through CTCF-mediated transcriptional reprogramming[J]. J Exp Med, 2022, 219(7): e20211779. |
| 19 | CHOI Y, SONG M J, JUNG W J, et al. Liver-specific deletion of mouse CTCF leads to hepatic steatosis via augmented PPARγ signaling[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(5): 1761-1787. |
| 20 | WANG W, REN G, HONG N, et al. Exploring the changing landscape of cell-to-cell variation after CTCF knockdown via single cell RNA-seq[J]. BMC Genomics, 2019, 20(1): 1015. |
| 21 | PINTO P B, DOMSCH K, LOHMANN I. Hox function and specificity: a tissue centric view[J]. Semin Cell Dev Biol, 2024, 152/153: 35-43. |
| 22 | AITKEN S J, IBARRA-SORIA X, KENTEPOZIDOU E, et al. CTCF maintains regulatory homeostasis of cancer pathways[J]. Genome Biol, 2018, 19(1): 106. |
| 23 | DAVIDSON I F, PETERS J M. Genome folding through loop extrusion by SMC complexes[J]. Nat Rev Mol Cell Biol, 2021, 22(7): 445-464. |
/
| 〈 |
|
〉 |